Host urothelial proteins and DNA

Host urothelial proteins and DNA refers to the broad set of molecular targets within the epithelial lining of the urinary tract, specifically the urothelium. This target designation is primarily used in the context of intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC), where therapeutic agents are delivered directly into the bladder (American Urological Association, 2023). The DNA within these cells is a primary target for alkylating agents like Mitomycin C and Thiotepa, which form covalent cross-links that inhibit DNA replication and trigger apoptosis (PubChem, CID 5746). Host proteins, including various enzymes and structural components, are also subject to modification or inactivation by these reactive chemical species. By targeting the cellular machinery of the urothelium, these drugs aim to eradicate residual malignant cells following transurethral resection of bladder tumors (TURBT). However, because these targets are present in both cancerous and healthy urothelial cells, treatment can result in localized adverse effects such as chemical cystitis and bladder wall irritation (StatPearls, 2023).

Other names

Urothelial DNAUrothelial cellular proteinsBladder mucosa molecular targets

The primary mechanism involves the chemical modification of DNA and proteins through alkylation or intercalation. For example, Mitomycin C undergoes intracellular activation to become a bifunctional alkylating agent that cross-links DNA, specifically at the N6 position of adenine and O6/N7 positions of guanine, thereby blocking DNA synthesis (NIH, 2023). Other agents like Valrubicin intercalate into DNA and inhibit topoisomerase II, leading to DNA strand breaks and cell death (PubChem, 2024).